Show simple item record

dc.contributor.authorZhang, Xi
dc.contributor.authorWan, Yunxia
dc.contributor.authorChata, Roberto
dc.contributor.authorBrazzale, Anthony
dc.contributor.authorAtherton, John J
dc.contributor.authorKostner, Karam
dc.contributor.authorDimeski, Goce
dc.contributor.authorPunyadeera, Chamindie
dc.date.accessioned2022-02-08T04:47:51Z
dc.date.available2022-02-08T04:47:51Z
dc.date.issued2016
dc.identifier.issn0021-9746
dc.identifier.doi10.1136/jclinpath-2016-203631
dc.identifier.urihttp://hdl.handle.net/10072/412132
dc.description.abstractAim Heart failure (HF) affects millions of older individuals in both developed and low/middle-income countries. Serum galectin-3 levels have been shown to have prognostic value. However, its use as a diagnostic biomarker has not been explored. The aim was to establish a saliva galectin-3 reference range and to demonstrate the potential diagnostic utility of salivary and serum galectin-3 levels in assessing HF. Methods Blood and saliva samples were collected from age-matched healthy controls (n=51) and patients with HF (n=63). Customised immunoassays were developed to quantify salivary galectin-3 levels. The diagnostic performances of these assays were evaluated by receiver operator characteristic (ROC) curves analysis. Results The galectin-3 concentrations were significantly elevated in saliva and serum samples of patients with HF compared with controls (p<0.001 and p<0.0001, respectively). Using ROC curve analysis, both serum and salivary galectin-3 gave area under the curve (AUC)=0.86 and AUC=0.73, respectively. There was also a significant correlation (r=0.4, p<0.01) between serum and salivary galectin-3 levels. Conclusions For the first time, we have quantified galectin-3 levels in human saliva and have demonstrated potential clinical utility in diagnosing HF. Further, larger multicentre clinical trials are needed before salivary galectin-3 levels can be implemented in a clinical setting.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherBMJ Publishing Group
dc.relation.ispartofpagefrom1100
dc.relation.ispartofpageto1104
dc.relation.ispartofissue12
dc.relation.ispartofjournalJournal of Clinical Pathology
dc.relation.ispartofvolume69
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchMedical microbiology
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3207
dc.subject.fieldofresearchcode3211
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsPathology
dc.subject.keywordsHEART-FAILURE
dc.subject.keywordsPLASMA GALECTIN-3
dc.titleA pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationZhang, X; Wan, Y; Chata, R; Brazzale, A; Atherton, JJ; Kostner, K; Dimeski, G; Punyadeera, C, A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva, Journal of Clinical Pathology, 2016, 69 (12), pp. 1100-1104
dcterms.dateAccepted2016-04-21
dc.date.updated2022-02-08T04:46:57Z
gro.hasfulltextNo Full Text
gro.griffith.authorPunyadeera, Chamindie
gro.griffith.authorZhang, Xi


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record